Program
Program
Recent Quotes
My Watchlist
Indicators
Local Stocks
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axonics Inc (NQ: AXNX )

70.37 +0.07 (+0.10%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axonics Inc

< Previous 1 2 3 4 5 6 7 Next >
Axonics to Participate in Upcoming Investor Conferences
From Axonics, Inc.
Via Business Wire
Axonics Acquires Technology to Facilitate Easier and Faster Placement of Implantable Leads for Sacral Neuromodulation
From Axonics, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2023
Via Benzinga
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
Axonics Modulation Tech Earnings Preview
Via Benzinga
Analyst Ratings for Axonics
Via Benzinga
2 Fast-Growing Healthcare Stocks to Buy and Hold
The innovative companies have made great gains in a short period of time. 
Via The Motley Fool
Axonics to Report First Quarter 2023 Financial Results on May 1
From Axonics, Inc.
Via Business Wire
Axonics Ranked No. 2 on the Financial Times 2023 List of the Fastest Growing Companies in the Americas
From Axonics, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2023
Via Benzinga
Axonics Posts Smaller Than Expected Quarterly Loss, Raises Guidance
Via Benzinga
Analyst Ratings for Axonics
Axonics (NASDAQ:AXNX) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Axonics to Participate in the SUFU 2023 Winter Meeting
From Axonics, Inc.
Via Business Wire
Axonics Reports Fourth Quarter and Fiscal Year 2022 Financial Results
From Axonics, Inc.
Via Business Wire
Axonics to Report Fourth Quarter 2022 Financial Results on March 1
From Axonics, Inc.
Via Business Wire
Axonics Risk/Reward Ratio Is Less Favorable, Analyst Says While Downgrading Stock
Needham downgraded Axonics Inc (NASDAQ: AXNX) from Buy to Hold. 
Via Benzinga
Axonics Receives FDA Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System
From Axonics, Inc.
Via Business Wire
Why Axonics Shares Are Trading Higher Today?
Axonics, Inc. (NASDAQ: AXNX) shares are trading higher after the company reported preliminary fourth-quarter and full-year 2022 total net revenue results above estimates. The company also issued FY23... 
Via Benzinga
Axonics Reports Preliminary Fiscal Year 2022 Revenue and Provides Fiscal Year 2023 Revenue Guidance
From Axonics, Inc.
Via Business Wire
Axonics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Axonics, Inc.
Via Business Wire
Axonics Receives Health Canada Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System
From Axonics, Inc.
Via Business Wire
Axonics® to Participate in the Piper Sandler Healthcare Conference
From Axonics, Inc.
Via Business Wire
Axonics® Ranked No. 4 on the 2022 Deloitte Technology Fast 500™ List of the Fastest Growing Companies in North America
From Axonics, Inc.
Via Business Wire
Axonics® Reports Third Quarter 2022 Financial Results
From Axonics, Inc.
Via Business Wire
Earnings Scheduled For October 31, 2022
Companies Reporting Before The Bell • Insperity (NYSE:NSP) is estimated to report quarterly earnings at $0.96 per share on revenue of $1.46 billion. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 21, 2022
Upgrades 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2022
Upgrades 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022
Upgrades 
Via Benzinga
Leading Medical Stocks, Including Sensus And Shockwave, Have Grown At Least 36% This Year
Biotech isn't the only place to make money in health care this year. 
Via Investor's Business Daily
Piper Sandler Maintains Overweight Rating for Axonics: Here's What You Need To Know
Piper Sandler has decided to maintain its Overweight rating of Axonics (NASDAQ:AXNX) and raise its price target from $82.00 to $84.00. Shares of Axonics are trading down 1.5% over the last 24 hours, at... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.